Immune checkpoint inhibitor‐induced autoimmune limbic encephalitis with positivity for anti‐Hu antibodies in a patient with small‐cell lung cancer: A case report and literature review
Open Access
- 25 November 2024
- journal article
- research article
- Published by Wiley in Respirology Case Reports
- Vol. 12 (11)
Abstract
In recent years, there has been an increasing number of studies on neurological symptoms induced as paraneoplastic neurological syndrome (PNS) or neurological immune‐related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). Herein, we report a 68‐year‐old male patient with small‐cell lung cancer who developed memory impairment and autonomic nervous system dysfunction after three courses of carboplatin, etoposide, and durvalumab therapy. Brain magnetic resonance imaging revealed hyperintense areas restricted to the bilateral temporal lobes. Moreover, based on the blood test results, the patient was strongly positive for anti‐neuronal nuclear antibodies. Hence, he was diagnosed with autoimmune limbic encephalitis (ALE). Corticosteroid pulse therapy was administered. After treatment, the patient exhibited gradual improvement in memory impairment. However, while tapering the prednisolone dose, the patient exhibited relapse of memory disturbance owing to ALE. It is challenging to distinguish PNS from neurological irAEs. However, ICI‐induced ALE with positivity for anti‐Hu antibodies has an extremely poor prognosis.Keywords
This publication has 11 references indexed in Scilit:
- Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint InhibitorsNeurology Neuroimmunology & Neuroinflammation, 2022
- Immune Checkpoint Inhibitor-Induced Limbic Encephalitis during Treatment with Atezolizumab in a Patient with Small-Cell Lung Cancer: A Case Report and Review of the LiteratureCase Reports in Immunology, 2022
- Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case ReportOncoTargets and Therapy, 2021
- Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesNeurology Neuroimmunology & Neuroinflammation, 2021
- Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute managementJournal of Neurology, Neurosurgery & Psychiatry, 2021
- Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative reviewTherapeutic Advances in Drug Safety, 2021
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitisNature Medicine, 2019
- Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitorsNature Reviews Clinical Oncology, 2019
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- A clinical approach to diagnosis of autoimmune encephalitisThe Lancet Neurology, 2016